Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. Show more

Location: | Website: www.kinnate.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$2.65

Open

$2.65

Volume

N/A

Day Range

$2.65 - $2.65

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.16%

Institutional Own.

82.58%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KIN-3248 (pan-FGFR inhibitor) Details Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KIN-7136 (MEK inhibitor) +/- exarafenib Details Solid tumor/s, Non-small cell lung carcinoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exarafenib (KN-2787) +/- binimetinib Details Cancer, Solid tumor/s, Melanoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.